502 related articles for article (PubMed ID: 29324897)
1. Serum galactose-deficient-IgA1 and IgG autoantibodies correlate in patients with IgA nephropathy.
Placzek WJ; Yanagawa H; Makita Y; Renfrow MB; Julian BA; Rizk DV; Suzuki Y; Novak J; Suzuki H
PLoS One; 2018; 13(1):e0190967. PubMed ID: 29324897
[TBL] [Abstract][Full Text] [Related]
2. Experimental evidence of pathogenic role of IgG autoantibodies in IgA nephropathy.
Moldoveanu Z; Suzuki H; Reily C; Satake K; Novak L; Xu N; Huang ZQ; Knoppova B; Khan A; Hall S; Yanagawa H; Brown R; Winstead CJ; O'Quinn DB; Weinmann A; Gharavi AG; Kiryluk K; Julian BA; Weaver CT; Suzuki Y; Novak J
J Autoimmun; 2021 Mar; 118():102593. PubMed ID: 33508637
[TBL] [Abstract][Full Text] [Related]
3. Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression.
Maixnerova D; Ling C; Hall S; Reily C; Brown R; Neprasova M; Suchanek M; Honsova E; Zima T; Novak J; Tesar V
PLoS One; 2019; 14(2):e0212254. PubMed ID: 30794576
[TBL] [Abstract][Full Text] [Related]
4. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy.
Berthoux F; Suzuki H; Thibaudin L; Yanagawa H; Maillard N; Mariat C; Tomino Y; Julian BA; Novak J
J Am Soc Nephrol; 2012 Sep; 23(9):1579-87. PubMed ID: 22904352
[TBL] [Abstract][Full Text] [Related]
5. A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases.
Yanagawa H; Suzuki H; Suzuki Y; Kiryluk K; Gharavi AG; Matsuoka K; Makita Y; Julian BA; Novak J; Tomino Y
PLoS One; 2014; 9(5):e98081. PubMed ID: 24858067
[TBL] [Abstract][Full Text] [Related]
6. Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes.
Berthelot L; Robert T; Vuiblet V; Tabary T; Braconnier A; Dramé M; Toupance O; Rieu P; Monteiro RC; Touré F
Kidney Int; 2015 Oct; 88(4):815-22. PubMed ID: 26061544
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers in IgA nephropathy: relationship to pathogenetic hits.
Hastings MC; Moldoveanu Z; Suzuki H; Berthoux F; Julian BA; Sanders JT; Renfrow MB; Novak J; Wyatt RJ
Expert Opin Med Diagn; 2013 Nov; 7(6):615-27. PubMed ID: 24175678
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis of IgA Nephropathy: Current Understanding and Implications for Development of Disease-Specific Treatment.
Knoppova B; Reily C; King RG; Julian BA; Novak J; Green TJ
J Clin Med; 2021 Sep; 10(19):. PubMed ID: 34640530
[TBL] [Abstract][Full Text] [Related]
9. Immune characteristics of renal allograft donors with mesangial IgA deposition.
Wang Z; Zhang X; Han W; Yu G; Ying Z; Xu X; Wang M; Zhou X; Lv J; Zhang H
Int Immunopharmacol; 2021 Feb; 91():107282. PubMed ID: 33370682
[TBL] [Abstract][Full Text] [Related]
10. Association of IgG co-deposition with serum levels of galactose-deficient IgA1 in pediatric IgA nephropathy.
Eison TM; Hastings MC; Moldoveanu Z; Sanders JT; Gaber L; Walker PD; Lau KK; Julian BA; Novak J; Wyatt RJ
Clin Nephrol; 2012 Dec; 78(6):465-9. PubMed ID: 23006340
[TBL] [Abstract][Full Text] [Related]
11. Effect of Immunosuppressive Drugs on the Changes of Serum Galactose-Deficient IgA1 in Patients with IgA Nephropathy.
Kim MJ; Schaub S; Molyneux K; Koller MT; Stampf S; Barratt J
PLoS One; 2016; 11(12):e0166830. PubMed ID: 27930655
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of Serum Biomarkers of Autoimmunity for Recurrence of IgA Nephropathy after Kidney Transplantation.
Berthoux F; Suzuki H; Mohey H; Maillard N; Mariat C; Novak J; Julian BA
J Am Soc Nephrol; 2017 Jun; 28(6):1943-1950. PubMed ID: 28255003
[TBL] [Abstract][Full Text] [Related]
13. Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy.
Yasutake J; Suzuki Y; Suzuki H; Hiura N; Yanagawa H; Makita Y; Kaneko E; Tomino Y
Nephrol Dial Transplant; 2015 Aug; 30(8):1315-21. PubMed ID: 26109484
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of galactose-deficient IgA are elevated in patients with IgA nephropathy but do not correlate to disease activity or progression.
Elíasdóttir S; Khramova A; Saeed A; Guron G; Boi R; Mölne J; Ebefors K; Nyström J
BMC Nephrol; 2023 Jun; 24(1):160. PubMed ID: 37286948
[TBL] [Abstract][Full Text] [Related]
15. A cross-sectional analysis of clinicopathologic similarities and differences between Henoch-Schönlein purpura nephritis and IgA nephropathy.
Sugiyama M; Wada Y; Kanazawa N; Tachibana S; Suzuki T; Matsumoto K; Iyoda M; Honda H; Shibata T
PLoS One; 2020; 15(4):e0232194. PubMed ID: 32324811
[TBL] [Abstract][Full Text] [Related]
16. Cellular signaling and production of galactose-deficient IgA1 in IgA nephropathy, an autoimmune disease.
Reily C; Ueda H; Huang ZQ; Mestecky J; Julian BA; Willey CD; Novak J
J Immunol Res; 2014; 2014():197548. PubMed ID: 25152896
[TBL] [Abstract][Full Text] [Related]
17. Aberrant Glycosylation of the IgA1 Molecule in IgA Nephropathy.
Novak J; Barratt J; Julian BA; Renfrow MB
Semin Nephrol; 2018 Sep; 38(5):461-476. PubMed ID: 30177018
[TBL] [Abstract][Full Text] [Related]
18. Glomerular Immunodeposits of Patients with IgA Nephropathy Are Enriched for IgG Autoantibodies Specific for Galactose-Deficient IgA1.
Rizk DV; Saha MK; Hall S; Novak L; Brown R; Huang ZQ; Fatima H; Julian BA; Novak J
J Am Soc Nephrol; 2019 Oct; 30(10):2017-2026. PubMed ID: 31444275
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of galactose-deficient IgA in children with IgA nephropathy and Henoch-Schönlein purpura.
Lau KK; Wyatt RJ; Moldoveanu Z; Tomana M; Julian BA; Hogg RJ; Lee JY; Huang WQ; Mestecky J; Novak J
Pediatr Nephrol; 2007 Dec; 22(12):2067-72. PubMed ID: 17943324
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis.
Suzuki H
Clin Exp Nephrol; 2019 Jan; 23(1):26-31. PubMed ID: 29740706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]